This company listing is no longer active
ASLAN Pharmaceuticals (ASLN) Stock Overview
A clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
ASLN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
ASLAN Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.60 |
| 52 Week High | US$22.16 |
| 52 Week Low | US$0.47 |
| Beta | 1.4 |
| 1 Month Change | -76.33% |
| 3 Month Change | -83.52% |
| 1 Year Change | -97.26% |
| 3 Year Change | -99.46% |
| 5 Year Change | -99.52% |
| Change since IPO | -99.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| ASLN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -76.5% | 3.2% | -0.6% |
| 1Y | -97.3% | 31.7% | 16.0% |
Return vs Industry: ASLN underperformed the US Biotechs industry which returned 11.4% over the past year.
Return vs Market: ASLN underperformed the US Market which returned 19.4% over the past year.
Price Volatility
| ASLN volatility | |
|---|---|
| ASLN Average Weekly Movement | 21.6% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: ASLN's share price has been volatile over the past 3 months.
Volatility Over Time: ASLN's weekly volatility has decreased from 31% to 22% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 35 | Carl Alan Jason Firth | aslanpharma.com |
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company’s clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd.
ASLAN Pharmaceuticals Limited Fundamentals Summary
| ASLN fundamental statistics | |
|---|---|
| Market cap | US$1.70m |
| Earnings (TTM) | -US$35.03m |
| Revenue (TTM) | US$12.00m |
Is ASLN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ASLN income statement (TTM) | |
|---|---|
| Revenue | US$12.00m |
| Cost of Revenue | US$0 |
| Gross Profit | US$12.00m |
| Other Expenses | US$47.03m |
| Earnings | -US$35.03m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -12.38 |
| Gross Margin | 100.00% |
| Net Profit Margin | -291.89% |
| Debt/Equity Ratio | -147.6% |
How did ASLN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/07/21 22:18 |
| End of Day Share Price | 2024/07/19 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ASLAN Pharmaceuticals Limited is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | BTIG |
| Nathaniel Calloway | Edison Investment Research |
| Yi Chen | H.C. Wainwright & Co. |